Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy

• Published in: Annals of surgical oncology 2022-08, Vol.29 (8), p.5307-5316
• Main Authors: Mori, Keiichiro, Schuettfort, Victor M., Katayama, Satoshi, Laukhtina, Ekaterina, Pradere, Benjamin, Quhal, Fahad, Sari Motlagh, Reza, Mostafaei, Hadi, Grossmann, Nico C., Rajwa, Pawel, Teoh, Jeremy YC, Resch, Irene, Fajkovic, Harun, Moschini, Marco, D’andrea, David, Abufaraj, Mohammad, Karakiewicz, Pierre I., Lotan, Yair, Scherr, Douglas, Egawa, Shin, Compérat, Eva, Shariat, Shahrokh F.
• Format: Article
• Language: English
• Subjects: Angiogenesis; Bladder cancer; Cell adhesion & migration; Cell adhesion molecules; Decision making; Medicine; Medicine & Public Health; Metastases; Oncology; Patients; Plasma; Plasma levels; Prediction models; Surgery; Surgical Oncology; Urologic Oncology; Urothelial carcinoma; Vascular cell adhesion molecule 1
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-022-11575-4

Background Angiogenesis-related marker vascular cell adhesion molecule-1 (VCAM-1) has been shown to be elevated in urothelial carcinoma of the bladder (UCB), but its predictive/prognostic role has not been determined. Thus, this study aimed to investigate the predictive/prognostic role of VCAM-1 for patients who have UCB treated with radical cystectomy (RC). Methods The study enrolled 1036 patients with clinically non-metastatic advanced UCB who underwent RC, and plasma VCAM-1 was evaluated preoperatively. The correlation of plasma VCAM-1 with pathologic and survival outcomes was assessed using binominal logistic regression and multivariable Cox regression analyses. Discrimination was assessed using the area under the curve and concordance indices. The clinical net benefit was evaluated using decision curve analysis (DCA). Results Preoperative VCAM-1 was significantly elevated in patients with adverse pathologic features. Higher VCAM-1 levels were independently associated with increased risk of lymph-node-metastasis (LNM), ≥pT3 disease, and non-organ-confined disease (NOCD ( p < 0.001 for each). Preoperative plasma VCAM-1 was independently associated with recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in pre- and postoperative multivariable models. Adding VCAM-1 to these predictive models improved their discriminatory ability to predict all outcomes by a significant margin. In the DCA, VCAM-1 addition to the reference models for prediction of LNM, NOCD, RFS, and CSS resulted in relevant improvement. Conclusions Elevated plasma VCAM-1 was associated with biologically and clinically aggressive UCB disease features. After validation, preoperative VCAM-1 may serve as a biomarker to help identify patients likely to benefit from intensified/multimodal therapy. In addition, VCAM-1 improved the discriminatory power of predictive/prognostic models and can be used to refine personalized clinical decision-making.